ASX:MIN
ASX:MINMetals and Mining

3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2%

With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these investments have the potential to offer significant upside when their true worth is recognized.
ASX:TLX
ASX:TLXBiotechs

Telix Pharmaceuticals (ASX:TLX) Boosts Growth with Cardinal Health Alliance and New FDA Submissions

Telix Pharmaceuticals (ASX:TLX) is experiencing significant growth, marked by a 65% revenue increase in the first half of 2024 and a raised revenue guidance. However, the company faces challenges such as high valuation and market competition. In the discussion that follows, we will explore Telix's core strengths, critical issues, growth opportunities, and potential threats to provide a comprehensive overview of its current business situation.